The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
NCT06243536 on ClinicalTrials.gov · last registry update 2024-02-06
60 participants. Its estimated completion date, 31 December 2024, has passed with no update to the record. Primary outcome, as filed: Eating Attitude Test (EAT-26) questionnaire score. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University Hospital Sestre Milosrdnice
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2024-02-01
- Primary completion
- 2024-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Eating Attitude Test (EAT-26) questionnaire score
Conditions studied
Type 2 Diabetes · Overweight · Disordered Eating Behaviors
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.